Nakatsuji, Teruaki
Hata, Tissa R.
Tong, Yun http://orcid.org/0000-0003-2003-1843
Cheng, Joyce Y. http://orcid.org/0000-0002-7317-7486
Shafiq, Faiza
Butcher, Anna M.
Salem, Secilia S.
Brinton, Samantha L.
Rudman Spergel, Amanda K. http://orcid.org/0000-0002-9418-7317
Johnson, Keli
Jepson, Brett
Calatroni, Agustin
David, Gloria
Ramirez-Gama, Marco http://orcid.org/0000-0003-4572-6115
Taylor, Patricia
Leung, Donald Y. M. http://orcid.org/0000-0002-0177-3844
Gallo, Richard L. http://orcid.org/0000-0002-1401-7861
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI117673 and 1UM1AI151958, R37AI052453, U19AI117673, R01AI153185, U19AI117673)
U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR076082)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1 TR002535)
Article History
Received: 1 June 2020
Accepted: 15 January 2021
First Online: 22 February 2021
Competing interests
: T.N. and R.L.G. are co-inventors of UCSD technology related to the bacterial antimicrobial peptides discussed herein. R.L.G. is co-founder and has equity interest in MatriSys Bioscience and Sente Inc. A.K.R.S.’s co-authorship of this publication does not necessarily constitute endorsement by the NIAID, the NIH or any other agency of the US government. All other authors declare no conflicts of interest.